2012 Pharmaceuticals Research Review
This review of pharmaceutical market research provides:
- Analysis and the future direction of treatments for neurodegenerative (i.e., progressive ataxia and weakness) disorders as the market efforts toward drug and therapy development evolve.
- Coverage of approved human antifungal therapeutics with a heavy focus on therapeutics in early development.
- Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs.
- Comprehensive analysis of the market for genitourinary drugs on a global basis.
- Current and future characteristics of the global markets for treatments for syndromes of dementia and movement disorders.
The pharmaceutical manufacturing industry in 2012 saw a slew of mergers and acquisitions, many of which were years in the planning. Outside pressures have created this “eat or be eaten” mentality, and in many respects the merger and acquisition activity simply trades some short-term problems for some problems that need to be dealt with over a longer time span.
The market news has not been all bad as the overall pharmaceutical market grew to a historic trillion dollar high point. This stems from growing middle class consumption in the BRIC region (Brazil, Russia, India and China) and other regions.
BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our coverage of this critically important global market. This review of pharmaceutical market research conducted by BCC Research in 2012 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.
This review includes highlights from the following reports on pharmaceutical markets published BCC Research:
- Antifungal Drugs: Technologies and Global Markets.
- Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness.
- Global Markets for Asthma and COPD Drugs.
- Genitourinary Drugs: Technologies and Global Markets.
- Global Markets for Treatments for Syndromes of Dementia And Movement Disorders.
We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs
- The global market for marine-derived drugs by type was around $4.8 billion in 2011, which is expected to be around $5.3 billion in 2012. This global market is forecasted to reach $8.6 billion by 2016 at a compound annual growth rate (CAGR) of 12.5% for the five year period of 2011 to 2016.
- The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015.
- The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession. The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%. The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.